Back to top
more

Ikena Oncology (IKNA)

(Delayed Data from NSDQ)

$1.74 USD

1.74
17,064

+0.01 (0.29%)

Updated Aug 28, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Ikena Oncology, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 175 157 232 162 -99,999
Receivables 0 0 0 0 NA
Notes Receivable 0 0 0 0 NA
Inventories 0 0 0 0 NA
Other Current Assets 3 3 4 3 NA
Total Current Assets 179 160 237 166 NA
Net Property & Equipment 2 3 2 1 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 0 0 0 0 NA
Deposits & Other Assets 5 4 2 1 NA
Total Assets 192 172 248 168 NA
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 NA
Accounts Payable 2 2 2 2 NA
Current Portion Long-Term Debt 0 0 0 0 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 9 8 6 5 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 0 9 17 21 NA
Total Current Liabilities 14 22 27 28 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 0 0 8 35 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 0 0 0 0 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 1 0 0 206 NA
Minority Interest (Liabilities) 0 0 0 0 NA
Total Liabilities 22 25 40 269 NA
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 NA
Common Stock (Par) 0 0 0 0 NA
Capital Surplus 452 362 353 10 NA
Retained Earnings -282 -214 -145 -111 NA
Other Equity 0 -1 0 0 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 170 147 208 -101 NA
Total Liabilities & Shareholder's Equity 192 172 248 168 NA
Total Common Equity 170 147 208 -101 0
Shares Outstanding 48.20 36.20 35.90 NA NA
Book Value Per Share 3.52 4.06 5.79 0.00 0.00

Fiscal Year End for Ikena Oncology, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 145 157 175 197 157
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 4 4 3 4 3
Total Current Assets 149 161 179 201 161
Net Property & Equipment 1 1 2 3 3
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 3 6 5 4 4
Total Assets 157 173 192 215 172
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 1 2 2 4 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 3 5 9 11 6
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 1 2
Total Current Liabilities 8 10 14 19 12
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 1 33 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 15 17 22 60 15
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 455 454 452 418 403
Retained Earnings -312 -299 -282 -263 -246
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 143 155 170 155 157
Total Liabilities & Shareholder's Equity 157 173 192 215 172
Total Common Equity 143 155 170 155 157
Shares Outstanding 48.20 48.20 48.20 44.10 42.30
Book Value Per Share 2.96 3.22 3.52 3.52 3.70